Immunology of the antiphospholipid syndrome: Antibodies, antigens, and autoimmune response

Thrombosis and Haemostasis

Volumn 82, Issue 2, 1999, Pages 656-661

  Roubey, Robert A S ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTIGEN; AUTOANTIBODY; BETA2 GLYCOPROTEIN 1; CARDIOLIPIN ANTIBODY; LUPUS ANTICOAGULANT; PROTHROMBIN;

ANTIPHOSPHOLIPID SYNDROME; AUTOIMMUNITY; CELLULAR IMMUNITY; CONFERENCE PAPER; HUMAN; IMMUNOASSAY; IMMUNOGENETICS; IMMUNOLOGY; NOMENCLATURE; NONHUMAN; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 0032725138     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1615893     Document Type: Conference Paper

References (62)

1. Roubey RAS. Immunology of the antiphospholipid antibody syndrome. Arthritis Rheum. 1996;39:1444-1454.
2. 2-glycoprotein I binding to phospholipid membranes. Thromb Haemost. 1998;80:610-614.
3. 2-glycoprotein I deficiency and the risk of thrombosis. Thromb Haemost. 1992;67:649-653.
4. 2-glycoprotein I deficiency. Lupus. 1998;7:S191.
5. 2-glycoprotein I gene targeting construct for disruption of the β2-GPI gene. Arthritis Rheum. 1998;41:S135.
6. 2-glycoprotein I. Biochim Biophys Acta. 1997;1339:217-225.
7. 2-glycoprotein I mediated by the kringle IV domain. Blood. 1997;90:1482-1489.
8. 2GPI) to endothelial cells is mediated through a high affinity interaction with annexin II. Blood. 1998;92:172A.
9. 2-glycoprotein I mediates the antibody binding to endothelial membranes and induces the expression of adhesion molecules. Clin Exp Rheumatol. 1995;13:179-185.
10. Simantov R, LaSala JM, Lo SK, Gharavi AE, Sammaritano LR, Salmon JE, Silverstein FL. Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J Clin Invest. 1995;96:2211-2219.
11. 2-Glycoprotein I is a requirement for anticardiolipin antibodies binding to activated platelets: differences with lupus anticoagulants. Blood. 1993;81:1255-1262.
12. 2-glycoprotein I-dependent manner. J Immunol. 1996;157:2201-2208.
13. 2-glycoprotein I is a major protein associated with very rapidly cleared liposomes in vivo, suggesting a significant role in the immune clearance of "non-self" particles. J Biol Chem. 1995;270:25845-25849.
14. 2-glycoprotein I in macrophage recognition. J Biol Chem. 1997;272:31113-31117.
15. 2-glycoprotein I autoantibodies and its relevance to anticardiolipin antibody quantitation. Thromb Haemost. 1996;75:725-730.
16. 2 -glycoprotein I in the absence of phospholipid. Importance of antigen density and bivalent binding. J Immunol. 1995;154:954-960.
17. Tincani A, Spatola L, Prati E, Allegri F, Ferremi P, Cattaneo R, Meroni P, Balestrieri G. The anti- 2-glycoprotein I activity in human anti-phospholipid syndrome sera is due to monoreactive low-affinity autoantibodies directed to epitopes located on native 2-glycoprotein I and preserved during species evolution. J Immunol. 1996;157:5732-5738.
18. 2-glycoprotein I antibody affinity. J Immunol. 1998;161:2038-2043.
19. 2-glycoprotein I reactivity of monoclonal anticardiolipin antibodies from patients with the antiphospholipid syndrome. Arthritis Rheum. 1994;37:1453-1461.
20. 2-glycoprotein I as an anticardiolipin cofactor determined using deleted mutants expressed by a baculovirus system. Blood. 1996;87:3262-3270.
21. Marquis D, Victoria E, Iverson GM. β2GPI-dependent anticardiolipin autoantibodies recognize an epitope on the first domain of β2GPI. Lupus. 1998;7:S176.
22. 2-glycoprotein I. Lupus. 1998;7:S176.
23. 2-glycoprotien I is potentiated by a distinct subgroup of anticardiolipin antibodies. Thromb Haemost. 1992;68:297-300.
24. 2-glycoprotein I. J Clin Invest. 1992;90:1100-1104.
25. Arnout J, Wittevrongel C, Vanrusselt M, Hoylaerts M, Vermylen J. Beta-2-glycoprotein I dependent lupus anticoagulants form stable bivalent antibody beta-2-glycoprotein I complexes on phospholipid surfaces. Thromb Haemost. 1998;79:79-86.
26. 2-glycoprotein I complexes to lipid membranes. Biochemistry. 1996;35:13833-13842.
27. Takeya H, Mori T, Gabazza EC, Kuroda K, Deguchi H, Matsuura E, Ichikawa K, Koike T, Suzuki K. Anti-β2-glycoprotein I (β2GPI) monoclonal antibodies with lupus anticoagulant-like activity enhance the β2GPI binding to phospholipids. J Clin Invest. 1997;99:2260-2268.
28. 2-glycoprotein I-dependent antiphospholipid antibodies. Blood. 1995;86:617-623.
29. Bevers EM, Galli M, Barbui T, Comfurius P, Zwaal RFA. Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost. 1991;66:629-632.
30. Rao LVM, Hoang AD, Rapaport SI. Mechanisms and effects of the binding of lupus anticoagulant IgG and prothrombin to surface phospholipid. Blood. 1996;88:4173-4182.
31. Arvieux J, Darnige L, Caron C, Reber G, Bensa JC, Colomb MG. Development of an ELISA for autoantibodies to prothrombin showing their prevalence in patients with lupus anticoagulants. Thromb Haemost. 1995;74:1120-1125.
32. Galli M, Beretta G, Daldossi M, Bevers EM, Barbui T. Different anticoagulant and immunological properties of anti-prothrombin antibodies in patients with antiphospholipid antibodies. Thromb Haemost. 1997;77:486-491.
33. Horbach DA, van Oort E, Derksen RH, De Groot PG. The contribution of anti-prothrombin-antibodies to lupus anticoagulant activity-discrimination between functional and non-functional anti-prothrombin-antibodies. Thromb Haemost. 1998;79:790-795.
34. 2-glycoprotein-I assay for discrimination between anticardiolipin antibodies associated with infection and increased risk of thrombosis. Br J Haematol. 1995;91:471-473.
35. Guerin J, Sim RB, Feighery C, Jackson J. Antibody recognition of complement regulatory proteins, factor H, CR1 and C4BP in antiphospholipid syndrome patients. Lupus. 1998;7:S180.
36. 2-glycoprotein I (and other proteins). Proc Natl Acad Sci USA. 1997;94:10356-10361.
37. Hörkkö S, Miller E, Dudl E, Reaven P, Curtiss LK, Zvaifler NJ, Terkeltaub R, Pierangeli SS, Branch DW, Palinski W, Witztum JL. Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. J Clin Invest. 1996;98:815-825.
38. Kapur A, Kelsey PR, Isaacs PE. Factor V inhibitor in thrombosis. Am J Hematol. 1993;42:384-388.
39. Oosting JD, Derksen RHWM, Bobbink IWG, Hackeng TM, Bouma BN, De Groot PG. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism? Blood. 1993;81:2618-2625.
40. Pengo V, Biasiolo A, Brocco T, Tonetto S, Ruffatti A. Autoantibodies to phospholipid-binding plasma proteins in patients with thrombosis and phospholipid-reactive antibodies. Thromb Haemost. 1996;75:721-724.
41. Carson CW, Comp PC, Esmon NL, Rezaie AR, Esmon CT. Thrombomodulin antibodies inhibit protein C activation and are found in patients with lupus anticoagulant and unexplained thrombosis. Arthritis Rheum. 1994;37:S296.
42. Matsuda J, Saitoh N, Gohchi K, Gotoh M, Tsukamoto M. Anti-annexin V antibody in systemic lupus erythematosus patients with lupus anticoagulant and/or anticardiolipin antibody. Am J Hematol. 1994;47:56-58.
43. Shibata S, Sasaki T, Harpel P, Fillit H. Autoantibodies to vascular heparan sulfate proteoglycan in systemic lupus erythematosus react with endothelial cells and inhibit the formation of thrombin-antithrombin III complexes. Clin Immunol Immunopathol. 1994;70:114-123.
44. Moore JE, Mohr CF. Biologically false positive serologic tests for syphilis. JAMA. 1952;150:467-473.
45. Moore JE, Lutz WB. The natural history of systemic lupus erythematosus: an approach to its study through chronic biologic false positive reactors. J Chron Dis. 1955;1:297-316.
46. Mujic F, Cuadrado MJ, Lloyd M, Khamashta MA, Page G, Hughes GR. Primary antiphospholipid syndrome evolving into systemic lupus erythematosus. J Rheumatol. 1995;22: 1589-1592.
47. Derksen RHWM, Gmelig-Meijling FH, De Groot PG. Primary antiphospholipid syndrome evolving into systemic lupus erythematosus. Lupus. 1996;5:77-80.
48. Casciola-Rosen LA, Anhalt G, Rosen A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med. 1994;179:1317-1330.
49. Smith HR, Hansen CL, Rose R, Canoso RT. Autoimmune MRL-1pr/1pr mice are an animal model for the secondary APS. J Rheumatol. 1990;17:911-915.
50. Hashimoto Y, Kawamura M, Ichikawa K, Suzuki T, Sumida T, Yoshida S, Matsuura E, Ikehara S, Koike T. Anticardiolipin antibodies in NZW × BXSB F1 mice: a model of antiphospholipid antibody syndrome. J Immunol. 1992;149:1063-1068.
51. 2-glycoprotein I and cardiolipin. J Immunol. 1996;2631-2641.
52. 2-glycoprotein I (β2GPI) breaks tolerance against the murine molecule. Lupus. 1998;7:S173.
53. 2-glycoprotein I bound to apoptotic thymocytes. J Autoimmun. 1998;11:413-424.
54. Blank M, Cohen J, Toder V, Shoenfeld Y, Induction of antiphospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal anti-cardiolipin antibodies. Proc Natl Acad Sci USA. 1991;88:3069-3073.
55. Blank M, Krause I, Lanir N, Vardi P, Gilburd B, Tincani A, Tomer Y, Shoenfeld Y. Transfer of experimental antiphospholipid-syndrome by bone marrow cell transplantation: the importance of the T cell. Arthritis Rheum. 1995;38:115-122.
56. Adachi Y, Inaba M, Sugihara A, Koshiji M, Sugiura K, Amoh Y, Mori S, Kamiya T, Genba H, Ikehara S. Effects of administration of monoclonal antibodies (anti-CD4 or anti-CD8) on the development of autoimmune diseases in (NZW × BXSB)F1 mice. Immunobiology. 1998;198:451-464.
57. Arnett FC, Olsen ML, Anderson KL, Reveille JD. Molecular analysis of major histocompatibility complex alleles associated with the lupus anticoagulant. J Clin Invest. 1991;87: 1490-1495.
58. Sebastiani GD, Galeazzi M, Morozzi G, Marcolongo R. The immunogenetics of the antiphospholipid syndrome, anticardiolipin antibodies, and lupus anticoagulant. Semin Arthritis Rheum. 1996;25:414-420.
59. Goel N, Ortel TL, Bali D, Anderson J, Gourley IS, Smith H, Morris CA, DeSimone M, Branch DW, Ford P, Berdeaux D, Roubey RA, Kostyu DD, Kingsmore SF, Thiel T, Amos C, Seldin MF. Familial antiphospholipid antibody syndrome: criteria for disease and evidence for autosomal dominant inheritance. Arthritis Rheum. In press.
60. Ida A, Hirose S, Hamano Y, Kodera S, Jiang Y, Abe M, Zhang D, Nishimura H, Shirai T. Multigenic control of lupus-associated antiphospholipid syndrome in a model of (NZW × BXSB) F1 mice. Eur J Immunol. 1998;28:2694-2703.
61. Ibnou-Zekri N, Iwamoto M, Fossati L, McConahey PJ, Izui S. Role of the major histocompatibility complex class II Ea gene in lupus susceptibility in mice. Proc Natl Acad Sci USA. 1997;94:14654-14659.
62. Fossati L, Iwamoto M, Merino R, Izui S. Selective enhancing effect of the Yaa gene on immune responses against self and foreign antigens. Eur J Immunol. 1995;25:166-173.